Kyverna Therapeutics · 2 weeks ago
Vice President, Research - New Technologies
United States
Full-time
Remote
Director/Executive
$300K/yr - $345K/yr
15+ years expKyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. They are seeking a visionary Vice President, Research to lead their discovery and early development organization, defining and executing the research strategy to transform autoimmune disease treatment through innovative immune cell therapies and next-generation platforms.
BiotechnologyLife ScienceTherapeutics
Responsibilities
Define and execute the company’s research and innovation strategy
Lead discovery, preclinical research, and early phase development
Shape the strategy for next-generation immune cell therapies and CAR-T innovation
Evaluate advances in CAR design, gene engineering, synthetic biology, immune tolerance, and related technologies
Build an innovation engine that generates future pipeline opportunities and platform extensions
Establish external collaborations with academic, biotech, and key opinion leaders
Monitor scientific and competitive landscapes to identify emerging opportunities
Build and advance a portfolio of next-generation therapeutic candidates
Evaluate next generation platform technologies to strengthen long-term competitive advantage
Prioritize discovery-stage investments and portfolio opportunities
Drive research focused on improving efficacy, safety, persistence, manufacturability, and patient experience
Assess novel immune cell engineering approaches and targeted immune reset strategies
Define platform evolution and pipeline expansion roadmaps
Partner with Business Development on external innovation and licensing opportunities
Ensure smooth transition from discovery to IND-enabling development
Support regulatory interactions and translational data packages
Collaborate with Clinical Development and Regulatory Affairs to enable clinical advancement
Establish governance, goals, and decision-making frameworks
Serve as a scientific advisor to cross functional teams
Represent Kyverna externally at conferences, advisory boards, and industry forums
Build relationships with key opinion leaders and external experts
Support business development, diligence, and strategic partnerships
Serve as a thought leader in immunology, autoimmune disease, and cell therapy innovation
Qualification
Required
PhD, MD, or equivalent in a relevant scientific discipline
15+ years of biotech/pharma experience with progressive leadership responsibility
Proven success leading discovery and translational research organizations
Deep expertise in immunology, autoimmune disease, or engineered immune cell therapies
Track record advancing programs from discovery through IND-enabling stages
Experience leading cross-functional scientific teams across research and early development
Strong understanding of end-to-end drug development (discovery through CMC and clinical development)
Experience in cell therapy, gene engineering, biologics, or related modalities
Experience advancing novel cellular engineering technologies into preclinical development
Knowledge of emerging in vivo CAR-T technologies, including advances in delivery, persistence, safety, manufacturing, and scalability
Experience in autoimmune, neuroimmunology, or immune-mediated diseases
Exposure to external innovation, platform evaluation, and strategic partnerships
Prior executive leadership experience in clinical-stage biotech
Strategic scientific thinker with strong innovation mindset
Executive presence and ability to influence across levels
Strong cross-functional collaborator across development, regulatory, and technical teams
Ability to balance scientific rigor with execution and business priorities
Clear communicator who translates complex science into strategic decisions
Benefits
This position is also eligible for bonus, benefits, and participation in Company’s stock plan.
Company
Kyverna Therapeutics
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.
51-200 employees
H1B Sponsorship
Kyverna Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
75%
Represents job field similar to this job
Management and Executive
Engineering and Development
Trends of Total Sponsorships
*2026 (1)
2025 (1)
2023 (1)
2021 (1)
Funding
Current Stage
Public CompanyTotal Funding
$295MKey Investors
Oxford Finance LLCNorthpond Ventures
2025-12-17Post Ipo Equity· $100M
2025-11-03Post Ipo Debt· $25M
2024-02-08IPO
Leadership Team
Warner Biddle
Chief Executive Officer
Gregory Martini
Chief Financial Officer
Recent News
2026-07-20
Company data provided by crunchbase